195 related articles for article (PubMed ID: 34913787)
21. Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab.
Miguel-Lillo B; Sánchez-Vidaurre S; Pérez Díaz L; Paravisini A
Pharmacol Res Perspect; 2023 Dec; 11(6):e01139. PubMed ID: 37920875
[TBL] [Abstract][Full Text] [Related]
22. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
Hanes V; Chow V; Pan Z; Markus R
Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275
[TBL] [Abstract][Full Text] [Related]
23. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
[TBL] [Abstract][Full Text] [Related]
24. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
Hummel M; Bosje T; Shaw A; Liu MS; Barve A; Kothekar M; Socinski MA; Waller CF
J Cancer Res Clin Oncol; 2022 Feb; 148(2):487-496. PubMed ID: 33866430
[TBL] [Abstract][Full Text] [Related]
25. Non-clinical pharmacology and toxicology studies of bevacizumab biosimilar LY01008.
Guangying D; Shuzhi M; Xiaoyin Z; Pengfei Y; Xin Y; Liang Y; Xin S; Baiping S; Changlin D; Hongbo W; Jingwei T
Eur J Pharmacol; 2022 Dec; 936():175383. PubMed ID: 36347321
[TBL] [Abstract][Full Text] [Related]
26. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
Eto T; Karasuyama Y; González V; Del Campo García A
Cancer Chemother Pharmacol; 2021 Oct; 88(4):713-722. PubMed ID: 34269848
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
[TBL] [Abstract][Full Text] [Related]
28. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects.
Lee HA; Kim S; Seo H; Kim S
Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163
[TBL] [Abstract][Full Text] [Related]
29. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin
Lickliter JD; Dadhania RN; Trivedi RK; Naveen Kumar SR; Reddy PK
Indian J Med Res; 2021 Mar; 154(3):509-519. PubMed ID: 35142643
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J
Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
Wynne C; Hamilton P; McLendon K; Stroissnig H; Smith M; Duijzings P; Ruffieux R; Otto H; Sattar A; Haliduola HN; Leutz S; Berti F
Expert Opin Investig Drugs; 2023 May; 32(5):417-427. PubMed ID: 37212315
[TBL] [Abstract][Full Text] [Related]
35. A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar.
Wang Y; Liu Z; Deng Q; Su Z; Xue J; Zhao Y; Yang H
Expert Opin Drug Metab Toxicol; 2023; 19(11):849-855. PubMed ID: 37526387
[TBL] [Abstract][Full Text] [Related]
36. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
Wynne C; Schwabe C; Lemech C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Kay R; Haliduola HN; Berti F
Expert Opin Investig Drugs; 2022 Sep; 31(9):965-976. PubMed ID: 35107050
[TBL] [Abstract][Full Text] [Related]
37. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants.
Boyce M; Wilkes D; Kaito H; Takanuma M; Arai Y
Int J Clin Pharmacol Ther; 2022 Jun; 60(6):280-290. PubMed ID: 35361328
[TBL] [Abstract][Full Text] [Related]
39. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Knight B; Rassam D; Liao S; Ewesuedo R
Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
[TBL] [Abstract][Full Text] [Related]
40. A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.
Wang J; Qi L; Liu L; Wang Z; Chen G; Wang Y; Liu X; Liu Y; Liu H; Tong Y; Liu C; Lei C; Wang X
Front Pharmacol; 2019; 10():905. PubMed ID: 31474863
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
